Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • GSK lifts annual...

    GSK lifts annual profit forecast after third quarter beat on vaccines strength

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-10-31T09:00:59+05:30  |  Updated On 17 Aug 2021 12:32 PM IST

    GSK now expects full-year profit to be roughly flat compared to last year at constant currency, up from a previous forecast of a fall of 3% to 5%.


    New Delhi: GlaxoSmithKline(GSK) Plc on Wednesday raised its annual profit forecast for the second time this year on the back of soaring sales of its Shingles vaccine, sending shares of the British drugmaker up nearly 3%.


    The drugmaker now expects full-year profit to be roughly flat compared to last year at constant currency, up from a previous forecast of a fall of 3% to 5%.


    Chief Executive Officer Emma Walmsley has set bold plans in motion to rejuvenate GSK, which has included the spin-off or sale of a number of businesses since she took over in 2017 and a greater focus on the company's pharmaceuticals business.


    Sales of Shingrix, launched in 2017, rose 76% to £535 million, way ahead of analysts' expectations of £464 million, leading vaccines unit sales to rise 15% to £2.31 billion.


    Read Also: GSK ovarian cancer drug Zejula gets USFDA nod for wider use


    Turnover rose 11% to £9.39 billion in the three months ended Sept. 30 from a year earlier. Adjusted earnings were 38.6 pence per share.


    Analysts on average had expected earnings of 33 pence and sales of £9.02 billion, according to a company-compiled consensus. The company said the new forecast reflects operating performance, increased investment in research and development as well as a lower expected effective tax rate of around 17% for the year.


    GSK shares were up nearly 3% to 1788 pence at 1213 GMT, their highest since May 2013.


    Read Also: GSK to sell anti-rabies vaccines Rabipur, Encepur to Bavarian Nordic for USD 1.1 billion

    annual profitGlaxoSmithKlineGSKpharmapharma companypharma newsresearch and developmentshingles vaccineShingrix
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok